NASDAQ:SGP Spyglass Pharma (SGP) Stock Price, News & Analysis $30.78 +1.10 (+3.71%) Closing price 04:00 PM EasternExtended Trading$30.72 -0.07 (-0.21%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Spyglass Pharma Stock (NASDAQ:SGP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyglass Pharma alerts:Sign Up Key Stats Today's Range$27.94▼$31.2150-Day Range$23.69▼$38.3752-Week Range$17.06▼$39.92Volume86,423 shsAverage Volume123,133 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$45.83Consensus RatingModerate Buy Company Overview SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients’ regular use of eye drops. The company’s lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma’s work centers on advancing this ophthalmic delivery platform and its lead program through clinical development. The company has not established a broad commercial product portfolio.AI Generated. May Contain Errors. Read More Spyglass Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreSGP MarketRank™: 3.50957592339 of 5 starsSpyglass Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 201st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingSpyglass Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSpyglass Pharma has a consensus price target of $45.83, representing about 48.9% upside from its current price of $30.78.Amount of Analyst CoverageSpyglass Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyglass Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyglass Pharma are expected to decrease in the coming year, from ($2.77) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyglass Pharma is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyglass Pharma is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpyglass Pharma has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.47% of the float of Spyglass Pharma has been sold short.Short Interest Ratio / Days to CoverSpyglass Pharma has a short interest ratio ("days to cover") of 12.05, which indicates bearish sentiment.Change versus previous monthShort interest in Spyglass Pharma has recently decreased by 5.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyglass Pharma does not currently pay a dividend.Dividend GrowthSpyglass Pharma does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.36 News SentimentSpyglass Pharma has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Spyglass Pharma this week, compared to 2 articles on an average week.Search Interest3 people have searched for SGP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Spyglass Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $32,430.00 in company stock, which represents 0.0031% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Spyglass Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,430.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsSpyglass Pharma has minimal institutional ownership at this time.Read more about Spyglass Pharma's insider trading history. Receive SGP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyglass Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGP Stock News HeadlinesSpyglass Pharma (NASDAQ:SGP) Director Ra Capital Management, L.P. Acquires 1,000 Shares of StockNovember 19 at 7:37 AM | insidertrades.comSpyglass Pharma (NASDAQ:SGP) Price Target Raised to $44.00November 16 at 2:13 AM | americanbankingnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 19 at 1:00 AM | Weiss Ratings (Ad)Spyglass Pharma (NASDAQ:SGP) Stock Price Expected to Rise, HC Wainwright Analyst SaysNovember 14, 2026 | americanbankingnews.comSpyGlass Pharma (SGP) RatiosNovember 13, 2026 | uk.investing.comSpyGlass Pharma Q3 2026: Loss Widens as Build-Out Costs SurgeNovember 12, 2026 | 247wallst.comSpyGlass Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11, 2026 | marketscreener.comMSpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatesNovember 11, 2026 | globenewswire.comSee More Headlines SGP Stock Analysis - Frequently Asked Questions How have SGP shares performed this year? Spyglass Pharma's stock was trading at $27.69 on February 17, 2026. Since then, SGP stock has increased by 11.2% and is now trading at $30.78. How were Spyglass Pharma's earnings last quarter? Spyglass Pharma, Inc. (NASDAQ:SGP) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.07. When did Spyglass Pharma IPO? Spyglass Pharma (SGP) raised $150 million in an initial public offering (IPO) on Friday, February 6th 2026. The company issued 9,375,000 shares at $15.00-$17.00 per share. How do I buy shares of Spyglass Pharma? Shares of SGP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/19/2026Citi Annual Global Healthcare Conference 202612/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SGP CIK1778922 Webwww.spyglasspharma.com Phone(949) 284-6904FaxN/AEmployees65Year Founded2019Price Target and Rating Average Price Target for Spyglass Pharma$45.83 High Price Target$62.00 Low Price Target$39.00 Potential Upside/Downside+48.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($7.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.46% Return on Assets-33.41% Debt Debt-to-Equity RatioN/A Current Ratio15.24 Quick Ratio15.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.29 per share Price / Book4.89Miscellaneous Outstanding Shares33,460,000Free FloatN/AMarket Cap$1.03 billion OptionableN/A BetaN/A Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:SGP) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyglass Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyglass Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.